1 | global health 6 february | | | | | | | 2 | 0.48% |
2 | on firstline nonnucleoside reverse | | | | | | | 2 | 0.48% |
3 | clinical outcomes with secondline | | | | | | | 2 | 0.48% |
4 | outcomes with secondline dolutegravir | | | | | | | 2 | 0.48% |
5 | with secondline dolutegravir in | | | | | | | 2 | 0.48% |
6 | secondline dolutegravir in people | | | | | | | 2 | 0.48% |
7 | virological failure on firstline | | | | | | | 2 | 0.48% |
8 | failure on firstline nonnucleoside | | | | | | | 2 | 0.48% |
9 | inhibitorbased regimens in south | | | | | | | 2 | 0.48% |
10 | health 6 february 2024 | | | | | | | 2 | 0.48% |
11 | regimens in south africa | | | | | | | 2 | 0.48% |
12 | in south africa a | | | | | | | 2 | 0.48% |
13 | south africa a retrospective | | | | | | | 2 | 0.48% |
14 | february 2024 read more | | | | | | | 2 | 0.48% |
15 | 6 february 2024 read | | | | | | | 2 | 0.48% |
16 | the lancet global health | | | | | | | 2 | 0.48% |
17 | lancet global health 6 | | | | | | | 2 | 0.48% |
18 | centre of excellence in | | | | | | | 2 | 0.48% |
19 | of excellence in hiv | | | | | | | 2 | 0.48% |
20 | april 2024 read more | | | | | | | 2 | 0.48% |
21 | research in south africa | | | | | | | 1 | 0.24% |
22 | innovation and the national | | | | | | | 1 | 0.24% |
23 | designated centre of excellence | | | | | | | 1 | 0.24% |
24 | foundation‘s designated centre of | | | | | | | 1 | 0.24% |
25 | for the aids programme | | | | | | | 1 | 0.24% |
26 | the aids programme of | | | | | | | 1 | 0.24% |
27 | aids programme of research | | | | | | | 1 | 0.24% |
28 | research foundation‘s designated centre | | | | | | | 1 | 0.24% |
29 | and innovation and the | | | | | | | 1 | 0.24% |
30 | read more download | | | | | | | 1 | 0.24% |
31 | science and innovation and | | | | | | | 1 | 0.24% |
32 | of science and innovation | | | | | | | 1 | 0.24% |
33 | department of science and | | | | | | | 1 | 0.24% |
34 | african department of science | | | | | | | 1 | 0.24% |
35 | south african department of | | | | | | | 1 | 0.24% |
36 | policy and is the | | | | | | | 1 | 0.24% |
37 | and policy and is | | | | | | | 1 | 0.24% |
38 | prevention read more | | | | | | | 1 | 0.24% |
39 | more news caprisa centre | | | | | | | 1 | 0.24% |
40 | hiv research and policy | | | | | | | 1 | 0.24% |